Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT04626791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell Lymphoma
Study identification
- NCT ID
- NCT04626791
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- Acalabrutinib Drug
- Bortezomib Drug
- Cyclophosphamide Drug
- Cytarabine Drug
- Doxorubicin Hydrochloride Drug
- Prednisone Drug
- Rituximab Biological
- Rituximab and Hyaluronidase Human Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2, 2021
- Primary completion
- Aug 2, 2024
- Completion
- Aug 2, 2028
- Last update posted
- Mar 11, 2024
2021 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ochsner NCI Community Oncology Research Program | New Orleans | Louisiana | 70121 | Withdrawn |
| Metropolitan-Mount Sinai Medical Center | Minneapolis | Minnesota | 55404 | Withdrawn |
| Mount Sinai Hospital | New York | New York | 10029 | Active, not recruiting |
| Carolinas Medical Center/Levine Cancer Institute | Charlotte | North Carolina | 28203 | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | Withdrawn |
| University of Washington Medical Center - Montlake | Seattle | Washington | 98195 | Recruiting |
| Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin | 53226 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04626791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2024 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04626791 live on ClinicalTrials.gov.